New fixed combination to replace a market leader?

Article

Dr Philippe Denis & Dr Thierry Zeyen explain why they feel that a new fixed combination, Azarga, could soon become the therapy of choice.

Key Points

Philippe Denis, MD, PhD and colleagues conducted a 12-month, multicentre study in which 437 patients with open-angle glaucoma or ocular hypertension were assigned randomly to receive either brinzolamide/timolol (n=220) or dorzolamide/timolol (n=217) twice a day and compared the safety and efficacy of each drug combination. The mean IOP and mean IOP change from baseline (after washout) was assessed at 8 and 10 am at week two and at months three and nine, and at 8 and 10 am and 4 pm at months six and 12.

Results showed that both fixed-combination agents had similar IOP-lowering effects. IOP levels for the brinzolamide/ timolol group ranged between 16.7 and 18.8 mmHg, compared with 16.9 to 19.4 mmHg for the dorzolamide/timolol group.

Each agent, however, showed distinctly different adverse event profiles, with dorzolamide/timolol demonstrating more eye irritation perceived as burning (2.7% in the brinzolamide/ timolol group versus 10.6% in the dorzolamide/timolol group) and pain perceived as stinging (2.7% in the brinzolamide/ timolol group versus 6.5% in the dorzolamide/timolol group).

According to Dr Denis, the most common adverse event caused by the brinzolamide/timolol combination was transient blurred vision. This may be more tolerable and acceptable to patients, compared with the eye irritation felt as burning and pain in the dorzolamide/timolol group.

"One explanation for this blurred vision might be the nature of the formulation," said Thierry Zeyen, MD, co-author of the study. "[Brinzolamide/timolol] is a suspension, not a solution. The suspension has a white deposit and needs to be shaken before administration and can cause a little haziness. The blurred vision, however, was intermittent and mainly occurred immediately after the administration of the drops."

"[Dorzolamide/timolol] has been used widely over the past several years. However, I believe the new product, [brinzolamide/timolol], may emerge as the therapy of choice, given its superior comfort and powerful efficacy compared with [dorzolamide/timolol]," Dr Denis said.

According to Dr Zeyen, it is not sufficient in today's glaucoma treatment simply to achieve an IOP of lower than 21 mmHg, but to achieve a target pressure.

"One of the targets that we often want to achieve is an IOP below 18 mmHg; if you look at the two combinations in this study, we achieved a statistically similar percentage of patients having an IOP below 18 mmHg [up to approximately 60%]," Dr Zeyen said.

According to Dr Denis, in past studies, fixed-combination brinzolamide/timolol has demonstrated significantly greater IOP-lowering effect compared with either of the single agents (brinzolamide or timolol) when used alone, indicating that fixed-combination therapy can improve IOP to a greater degree than monotherapy.

Several different classes of IOP-lowering agents are used to treat glaucoma and ocular hypertension, including prostaglandin analogues (PGAs), beta-blockers, alpha-agonists, and carbonic anhydrase inhibitors (CAIs). PGA/beta-blocker combinations tend to be the most effective agents for reducing IOP, and brinzolamide/timolol and dorzolamide/timolol are both similar in efficacy to PGAs used as monotherapy. Beta-receptor antagonists, CAIs, and alpha-agonists used alone have been shown to have a lower efficacy than combination drugs such as brinzolamide/timolol and dorzolamide/timolol.

This increased efficacy, combined with the reduction in irritation and pain in eyes treated with the brinzolamide/timolol combination, may make this therapy the patients' preferred choice, Dr Denis reiterated. "Fortunately," he continued, "Ophthalmologists can support this choice because [brinzolamide/timolol] produces IOP-lowering results that are equal to [dorzolamide/timolol]."

Related Videos
Paul Harasymowycz, MD
Ms Neeru Vallabh on a virtual call with Ophthalmology Times Europe
Fritz Hengerer, MD, PhD, Director, Eye Hospital at Bürgerhospital, Frankfurt, Germany
Dr Sheng Lim, professor of glaucoma studies at St Thomas' Hospital, London
Kasperi Kankare at the iCare booth at ESCRS
Disrupting the glaucoma treatment paradigm with novel femtosecond laser from ViaLase
2-year data in contralateral eye evaluation gives edge to iStent inject over Hydrus stent
© 2024 MJH Life Sciences

All rights reserved.